Trading Statement

Proteome Sciences plc                             

                       License Agreement in Lung Cancer                        

                              and Trading Update                               

6th January, 2009 Proteome Sciences plc has entered into a non-exclusive
license agreement with Oncimmune Limited in lung cancer for the use of its
Annexin 1 and Annexin 2 autoantibody patents for the fields of diagnosis and
for monitoring treatment. It is anticipated that a panel test will be launched
in the first half of 2009.

Terms of the license agreement were not disclosed but Proteome Sciences will
receive royalties from product sales.

Following the successful launch of TMT® reagents by Thermo Fisher earlier this
year, feedback continues to be strongly favourable and the visibility of
isobaric mass tagging will become increasingly apparent in revenues.

Proteome Sciences is pleased to announce that it has successfully increased the
plexing rates for its TMT® tags, and that 12 and 18-plex TMT® will be available
in 2009.

Proteome Sciences continues to make strong progress in other disease
applications and is in advanced negotiations to out-license further candidates
in its biomarker portfolio in both stroke and Alzheimer's disease and also from
ProteoSHOP® services activities. Whilst these are expected to be reflected in
revenue, the Board has thought it prudent to agree in principle to increase the
loan facility available from the CEO, should it be required.

2008 has been a transformational year for the Company and it looks forward with
confidence to further realising its potential in 2009.

                                     Ends                                      

For further information please contact:

Proteome Sciences plc

www.proteomics.com Tel: [phone]

Christopher Pearce, Chief Executive Officer James Malthouse, Finance Director

Dr. Ian Pike, Chief Business Officer

                               Public Relations                                

IKON Associates Coast Communications

Adrian Shaw Matt Baldwin

Tel: [phone] Tel: [phone]

Mobile: [phone] Mobile: [phone]

Email: [e-mail] Email: [e-mail]

Nominated Adviser

Teathers

Shaun Dobson / Claes Spång

Tel: [phone]

Lung Cancer-Background

  * Most common global cancer
   
  * Leading cause of cancer death
   
  * US screening population - 71.5m
   
  * New cases annually (US) - 213,000
   
  * Annual deaths from lung cancer (US) - 160,390
   
  * 5 year survival rate - 16%
   
About Proteome Sciences:

Proteome Sciences is a leading biomarker CRO providing protein biomarker
discovery, validation and assay development services. The Company's MS
Biomarker Assay system (MBA) uses its proprietary isobaric Tandem Mass Tags
(TMT®) and reference materials combined with isotope dilution mass
spectrometry. Highly multiplexed assays can be developed in weeks and are
suitable for screening 10's to 100's of candidate biomarkers in validation
studies. Assays for validated biomarkers can be rapidly developed using the
same isotope dilution mass spectrometry format, or can be transferred for
immunoassay development.

The Company's own research is focused on neurological and neurodegenerative
conditions and it has discovered and patented blood biomarkers in stroke and
brain damage as well as several cancers, solid organ transplant rejection and
Alzheimer's disease. Proteome Sciences is based in Cobham, UK with facilities
in London and Frankfurt.

About Oncimmune:

For more information on OncImmune visit www.oncimmune.com or 
www.oncimmune.co.uk.